Eli Lilly and Co. (NYSE: LLY) will continue its fight against type 1 diabetes with the European Foundation for the Study of Diabetes and the Juvenile Diabetes Research Foundation. The entities have announced a research collaboration, that started in 2015, will continue through 2020.
The program encourages research to better understand type 1 diabetes by providing grants to nonprofit institutes in Europe. The program has awarded 19 research grants including for beta cell technology and regeneration, therapies for improved glycemic control, among many others in Europe since its establishment. "Living with type 1 diabetes is a constant balancing act for those affected, and the disease still remains insufficiently understood," said Professor Stefano Del Prato, chairman of EFSD. "Together with Lilly and JDRF, we are committed to fund promising scientific research in Europe to prevent, treat and finally cure type 1 diabetes and its complications."
The organization hopes to promote biomedical and clinical research, to quicken the practical application of advances and encourage research translation in Europe. "We remain committed to our mission to make the lives of people with diabetes better by advancing cutting-edge research. We are pleased to continue our collaboration with important organizations like EFSD and JDRF to advance that goal," said Lilly VP of Diabetes Research and Clinical Investigation Ruth Gimeno, Ph.D. "The success of the programme over the past three years inspired us to continue the relationship and investment for the next three years."
For more information, and to apply for 2018 grants, click here.